Glecaprevir is an antiviral medication primarily used to treat chronic hepatitis C virus (HCV) infections. It belongs to a class of drugs known as direct-acting antivirals (DAAs), which target specific steps in the HCV life cycle to inhibit the virus's ability to replicate. Glecaprevir is often combined with another antiviral, pibrentasvir, to enhance its effectiveness and broaden its range of action against different HCV genotypes.
Glatiramer acetate is a medication primarily used to treat multiple sclerosis (MS), a chronic disease that affects the central nervous system. It is a synthetic mixture of polypeptides designed to resemble myelin basic protein, which is a component of the myelin sheath that protects nerve fibers. By modulating the immune system, Glatiramer acetate helps reduce the frequency of relapses in patients with relapsing forms of MS.
Givosiran is a medication designed to treat acute hepatic porphyria (AHP), a rare genetic disorder that affects the production of heme, a vital component of hemoglobin in red blood cells. This condition can lead to severe abdominal pain, neurological complications, and other debilitating symptoms. Givosiran works by targeting the underlying cause of AHP, providing patients with a new option for managing their condition.
Gilteritinib is a targeted therapy medication primarily used in the treatment of acute myeloid leukemia (AML) with specific genetic mutations. It is classified as a tyrosine kinase inhibitor, which means it works by blocking certain proteins that promote the growth of cancer cells. Gilteritinib is particularly effective for patients whose leukemia has relapsed or is refractory to other treatments, especially those with mutations in the FLT3 gene.
Gentamicin sulfate is an antibiotic medication that belongs to the aminoglycoside class. It is primarily used to treat various bacterial infections, particularly those caused by Gram-negative bacteria. Gentamicin works by inhibiting bacterial protein synthesis, effectively killing bacteria by disrupting essential protein synthesis. It is often administered in a hospital setting, especially for serious infections, and can be given through injections or topical applications.
Gemtuzumab ozogamicin is a targeted cancer therapy primarily used in the treatment of acute myeloid leukemia (AML). It is an antibody-drug conjugate consisting of a monoclonal antibody linked to the cytotoxic agent calicheamicin. This innovative approach aims to minimize damage to healthy cells while effectively targeting malignant ones.
Gemtuzumab ozogamicin is approved for specific medical uses, particularly in the treatment of:
Gemifloxacin is an antibiotic belonging to the fluoroquinolone class, primarily used to treat bacterial infections. It is effective against a variety of gram-positive and gram-negative bacteria, making it a valuable option for treating respiratory tract infections, including pneumonia and bronchitis. Gemifloxacin works by inhibiting bacterial DNA replication, which ultimately leads to the death of the bacteria.
Gemifloxacin is approved for several medical uses, including:
Gemfibrozil is a medication primarily used to manage cholesterol levels in the body. It belongs to a class of drugs known as fibrates, which are effective in lowering triglycerides and increasing high-density lipoprotein (HDL) cholesterol, often referred to as "good" cholesterol. By improving lipid profiles, Gemfibrozil may help reduce cardiovascular risk in selected patients with dyslipidemia, particularly those with high triglycerides and low HDL cholesterol.
Gemcitabine is a chemotherapy medication primarily used to treat various types of cancer, including pancreatic, lung, breast, and bladder cancers. It belongs to a class of drugs known as nucleoside analogs, which work by interfering with the growth and spread of cancer cells in the body. Gemcitabine is often administered in a clinical setting, either alone or in combination with other cancer treatments, to enhance its effectiveness.
Gemcitabine is approved for several medical uses, including:
Gefitinib is a targeted cancer therapy primarily used to treat non-small cell lung cancer (NSCLC). It belongs to a class of medications known as epidermal growth factor receptor (EGFR) inhibitors. By blocking the action of the EGFR protein, gefitinib helps to slow down or stop the growth of cancer cells that rely on this pathway for survival and proliferation. This medication is often prescribed for patients whose tumors have specific mutations in the EGFR gene, making it a personalized treatment option.
